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Malignant fibrous histiocytoma (MFH) is a rare neoplasm exhibiting a propensity for aggressive clinical behavior.
Effective treatment modality is surgical resection with wide margins, but its rate of recurrence and metastasis is
still high. Early detection and complete excision of the tumor is necessary. A MFH of the occipital developed in a
51-year-old woman eight years after surgery and radiation for medulloblastoma of the cerebellar vermis. The
secondary neoplasm arose at the site of tumor resection within the irradiated field, and was resected. The development
of sarcomas is a recognized complication of radiation therapy. The final diagnosis after the operation was MFH.
Radiation-induced sarcoma (RIS) is well known, but radiation-induced MFH is relatively rare in the head and neck
region, especially in the occipital. The imaging findings are not diagnosis specific, but strict follow-up within the
radiation field by computerized tomography (CT) and magnetic resonance imaging (MRI) and appreciation of the
expected latency period may help in providing the diagnosis of RIS.
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Malignant fibrous histiocytoma (MFH) is one of the most
common soft tissue sarcomas of adulthood and has been
reported in various organs. The site of primary origin
tends to be mainly in the extremities followed by the
trunk, the head, and the neck [1]. MFH are rare tumors
within the central nervous system. However, they have
been reported in the brain, dura mater, cranial bones,
spine and peripheral nerves [2,3]. Radiotherapy is one
of the most important treatments of malignant tumors
in the head and neck region, but it is known to induce
major side effects such as radionecrosis and oncogenesis.
MFH has been reported to occur with increased frequency
in patients who have been treated with radiotherapy for
malignant disease [4]. The purpose of this report is to
improve the understanding of the clinical behavior, pre-
dictors of biological aggressiveness, and histological and
immunohistochemical features of MFH after radiotherapy
for medulloblastoma of the cerebellar vermis.* Correspondence: zjt_ttyy@sina.com
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Clinical presentation
History and examination
A 51-year-old woman was first admitted at age 43 years
in July 2005. A midline suboccipital craniotomy of the
cerebellar vermis was performed in our department after
medulloblastoma was diagnosed (Figure 1A). Postoperative
irradiation was delivered in daily doses of 2 Gy, totaling
an overall dose of 60 Gy. Her five-year follow-up was
completed. She returned to our hospital eight years after
surgery (in July 2013), because of bilateral blurry vision for
two months. Neurological examination revealed bilateral
papilledema and slight cerebellar ataxia. No abnormality
was found on routine hematologic examination or uri-
nalysis. Magnetic resonance imaging (MRI) showed an
expansive and heterogeneous enhanced contrast mass
with an irregular outline involving the right cerebellar
hemispheres, posterior fossa dura, occipital bone, and the
torcular herophili measuring 5.2 × 3.2 × 3.2 cm, consistent
with recurrent medulloblastoma (Figure 2A,B,C).Operation and pathological findings
The patient underwent a midline suboccipital craniectomy
and complete resection of the tumor. Afterwards, total
closure of the dura defect was completed by reconstructionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pathological characteristics of the patient. A) High-power photomicrograph of the lesion, eight years previously, which was diagnosed as
medulloblastoma (H & E, 200×). B) High-power photomicrograph showing proliferation of pleomorphic spindle-shaped cells having large irregular nuclei
with hyperchromasia (H & E, 200×). C-I) Photomicrograph of tumor with immunohistochemical stain (200×). C) Vimentin demonstrating a strongly positive
reaction in the tumor cells. D) CD68 demonstrating a strongly positive reaction in the tumor cells. E) Fibronectin (FN) demonstrating a strongly positive
reaction in the tumor cells. F) Desmin showing negative reaction in the tumor cells. G) S-100 showing negative reaction in the tumor cells. H) Cytokeratins
showing negative reaction in the tumor cells. I) Ki-67 (MIB-1) demonstrating positive reaction in the tumor cells. The MIB-1 labeling index is 10%.
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operatively the tumor was very vascular, gritty, necrotic
in some areas and corroded the occipital bone. Postop-
erative early stage MRI confirmed no residual mass lesion
(Figure 2D,E,F). Histopathological examination revealed a
MFH. Hematoxylin and eosin (H & E) stained slides re-
vealed anaplastic proliferation of spindle-shaped cells
admixed with atypical giant cells arranged in fascicular
and storiform patterns (Figure 1B). These cells contained
typical hyperchrome nuclei with moderate cytoplasms
and mitosis. The immunohistochemical stains showed
vimentin, CD68 and fibronectin (FN) expression by the
tumor cells (Figure 1C,D,E). Desmin, S-100 and cyto-
keratins were negative (Figure 1F,G,H). The Ki-67 pro-
liferation index was 10% (Figure 1I). Genomic DNA
was isolated from peripheral blood mononuclear cellsaccording to standard protocols. For mutation analysis
of the complete coding region and the exon–intron
junctions of MLH1 and MSH2 in patients with micro-
satellite instability, direct DNA sequencing after PCR
amplification was applied [5,6]. Genomic mutations in
MLH1 or MSH2 were not detected in our patient.
Postoperative follow-up
The postoperative course was unremarkable and the
patient was discharged after seven days. She rejected
any radiotherapy or chemotherapy protocol in follow-
up treatment. Follow-up MRI and whole-body positron
emission tomography-computed tomography (PET-CT)
in the postoperative sixth month demonstrated tumor
non-recurrence at the same location and non-distant
metastasis (Figure 2G,H,I).
Figure 2 MR images showing the MFH of the posterior cranial fossa in preoperative and postoperative follow-up. A, B, C) MR images
showing an expansive mass of the posterior cranial fossa with an irregular outline involving the right cerebellar hemispheres, posterior fossa dura,
occipital bone and the torcular herophili. The signal intensity of the lesion is slightly hyperintense on the T1-weighted Gd-enhanced image. T1-weighted
Gd-enhanced image showing moderate heterogeneous enhancement throughout the lesion. D, E, F) Postoperative early stage MR images showing no
residual mass lesion. G, H, I) Follow-up MRI on the postoperative sixth month showing tumor non-recurrence. MR, magnetic resonance.
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MFH is one of the potentially devastating sarcomas in
middle-aged or elderly adults, frequently arising from the
proximal end of the extremities and in the retroperito-
neum [7]. It is uncommon in the head and neck region,
its frequency in this region being only 1% to 3% of all
MFHs [8]. Clinical manifestations of intracranial MFH
are various and mainly depend on the location of the
tumor. Occipital MFH has no distinct clinical feature
that could aid in its recognition. The diagnosis of MFH
is based primarily upon excellent sampling in conjunctionwith a targeted panel of immunohistochemistry [9]. MFH
tumor is composed of an admixture of spindle-shaped
fibroblastic tumor cells and bizarre mononuclear histio-
cytic tumor cells arranged in a storiform pattern with
some multinucleated giant cells [7]. Immuno-positivity
for vimentin, CD68 and Ki-67 has been demonstrated
in MFH and is helpful for diagnosis. The tumor tissue
should be immune-negative for S-100 protein and cyto-
keratins. The differential diagnosis of MFH can be diffi-
cult because of its similarity to other sarcomas composed
of spindle cells, such as spindle cell carcinoma, carcino-
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routine staining does not allow distinction of this sar-
coma from others, especially when the cells are pleo-
morphic. Although the characteristic patterns, such as
the storiform and antler-like patterns, are useful, immu-
nohistochemical staining was helpful for the diagnosis in
our case.
Brieger et al. describe two patients with Lynch syn-
drome-associated MFH. Both patients carried a MSH2
germline mutation and a mutator phenotype with loss
of MSH2 expression could be demonstrated in both
MFH [10]. This finding further supports the potential
risk of patients with Lynch syndrome to develop a MFH
as a consequence of the underlying MMR gene germline
mutation [10,11]. In our case, the genomic mutations
in MLH1 or MSH2 were not detected, and the clinical
presentation also did not confirm the diagnosis of Lynch
syndrome-associated MFH.
MFH has been reported to be more common among
patients who have received radiotherapy [12]. Ionized
radiation is clearly known to trigger sarcoma formation
[13]. The following criteria for defining a radiation induced
sarcoma (RIS) have been proposed by Cahan et al. [14]: (1)
evidence of an initial distinct malignant tumor different
from the subsequent sarcoma; (2) development of the
second malignant tumor in an irradiated field; (3) long
interval between radiation and development of the sar-
coma (a latency period of not less than five years); and
(4) histological confirmation of sarcoma. The present
case fulfilled all these criteria.
It is difficult to analyze the relationship between the
total irradiation dose received and the incidence of RIS
of the head and neck. Kirova et al. [15] showed that most
reported cases of RIS after breast irradiation occurred after
the administration of 60 to 80 Gy, with a minimal dose of
10 Gy, in standard fractions. Karlsson et al. [16] found that
the risk of sarcoma other than angiosarcomas increased
linearly with a total dose of 150 to 200 J, stabilizing at
higher energies. Pitcher et al. [5] believe that RIS may ap-
pear following radical radiation therapy regardless of the
photon energy. However, no available studies provide data
on the relationship between the prescribed radiation dose
and RIS. RIS typically occurs within or at the edge of the
radiation field [6]. Radiation doses greater than 50 Gy
cause complete devitalization and bone death, while lower
doses greater than 30 Gy are associated with permanent
damage to the reparative mechanisms [17]. The edge of
the radiation field is, therefore, at particular risk for the
development of a secondary malignancy. The lack of
homogeneity of the dose at the periphery of the radiation
field also results in an area that has received less radiation
than the putative tumor dose. The radiation dose here
may be insufficient to kill all viable cells, but may be
sufficient to cause cell damage and genetic mutations.A disorganized reparative proliferation may then act as
an initiating factor in tumor development.
The RIS is characterized by an aggressive behavior, with
a high incidence of local recurrence and distant metastasis
[18]. In our patient, the recurrent disease and distant
metastasis did not occur within a few months postopera-
tively. The overall five-year survival of RIS ranges between
10% and 30% [18,19]. Most papers quote a poor outcome
for RIS in the head and neck; for instance, Mark et al. [20]
reported a year disease-free survival of only 8%. Wang
et al. [21] reported that the five-year disease-free survival
and five-year overall survival rates of radiation-induced
MFH of the sinonasal tract were 0 and 5.9%.
The preferred treatment is surgical resection whenever
the site and size of tumor allow it. Radical en bloc resec-
tion is required because of the aggressiveness of MFH,
both locally and remotely [22]. Sabesan et al. [23] reported
that marginal resection of MFH of the head and neck car-
ries a local recurrence rate of up to 85%, whereas radical
resection has a local recurrence risk of only 27%. Because
of the technical difficulty of determining adequate surgical
margins and the poor healing and wound complications
associated with radiation changes, surgical management of
RIS in the posterior fossa is also challenging. Radiation
therapy for radiation-induced MFH is effective in some
cases but not in others [24]. The effectiveness of chemo-
therapy is also controversial and has yet to demonstrate
definitive benefit [9]. Ettinger et al. [25] reported excellent
results using postoperative cisplatin and doxorubicin
in patients with non-metastatic osteosarcoma. A recent
study by Hugate et al. [26] reported that neoadjuvant
chemotherapy (intraarterial cisplatin and intravenous
doxorubicin) improved survival rates of primary high-
grade extremity osteosarcoma and MFH of the bone.
Kocer et al. [27] showed that neoadjuvant chemotherapy
was an effective method for radiation-induced sternal
MFH. In planning the surgical resection, the size of the
tumor before chemotherapy should be considered as the
initial size and surgical margins should be determined
accordingly. Ko et al. [28] reported that exploitation of
more effective chemotherapy is necessary to improve
the tumor-free survival of patients with radiation-induced
MFH in the head and neck region. With so few reported
cases of RIS, it is difficult to establish the optimal treat-
ment. Initial radical surgery is usually the effective treat-
ment for achieving long-term survival because adjuvant
and palliative treatments are not so effective [1].
Conclusions
A poor prognosis can be expected because extensive re-
moval of the MFH is not easily accomplished. Owing to
its high rate of recurrence and metastasis, early detection
and complete excision of the tumor is necessary. The
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follow-up within the radiation field by CT and MRI and
appreciation of the expected latency period may help in
providing the diagnosis of RIS.
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